IWC
VRTX icon

Integrated Wealth Concepts’s Vertex Pharmaceuticals VRTX Stock Holding History

Integrated Wealth Concepts’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.08M Sell
4,668
-53
-1% -$24.7K 0.02% 730
2025
Q4 		$2.14M Buy
4,721
+147
+3% +$63.4K 0.03% 515
2025
Q3 		$1.79M Buy
4,574
+244
+6% +$102K 0.02% 717
2025
Q2 		$1.93M Sell
4,330
-384
-8% -$177K 0.02% 629
2025
Q1 		$2.29M Sell
4,714
-188
-4% -$87.6K 0.03% 546
2024
Q4 		$1.97M Sell
4,902
-207
-4% -$96K 0.02% 556
2024
Q3 		$2.38M Buy
5,109
+1,772
+53% +$851K 0.03% 504
2024
Q2 		$1.56M Buy
3,337
+159
+5% +$69K 0.02% 588
2024
Q1 		$1.33M Buy
3,178
+283
+10% +$120K 0.02% 652
2023
Q4 		$1.18M Hold
2,895
– – 0.02% 659
2023
Q3 		$1.01M Sell
2,895
-15
-0.5% -$5.25K 0.02% 689
2023
Q2 		$1.02M Buy
2,910
+919
+46% +$310K 0.02% 670
2023
Q1 		$627K Buy
+1,991
New +$597K 0.01% 778
2022
Q4 		– Sell
-733
Closed -$212K – 1082
2022
Q3 		$212K Sell
733
-51
-7% -$14.7K 0.01% 847
2022
Q2 		$221K Sell
784
-182
-19% -$48.7K 0.01% 864
2022
Q1 		$252K Sell
966
-287
-23% -$68.1K 0.01% 803
2021
Q4 		$275K Sell
1,253
-114
-8% -$22.2K 0.01% 817
2021
Q3 		$248K Sell
1,367
-622
-31% -$121K 0.01% 811
2021
Q2 		$401K Sell
1,989
-225
-10% -$47.1K 0.01% 583
2021
Q1 		$476K Buy
2,214
+155
+8% +$34K 0.02% 480
2020
Q4 		$487K Sell
2,059
-683
-25% -$157K 0.02% 420
2020
Q3 		$746K Buy
2,742
+642
+31% +$177K 0.05% 265
2020
Q2 		$610K Buy
2,100
+8
+0.4% +$2.17K 0.04% 248
2020
Q1 		$498K Buy
2,092
+366
+21% +$84K 0.05% 225
2019
Q4 		$378K Sell
1,726
-50
-3% -$10.1K 0.03% 314
2019
Q3 		$301K Buy
1,776
+66
+4% +$11.7K 0.03% 313
2019
Q2 		$314K Buy
1,710
+519
+44% +$90.7K 0.04% 264
2019
Q1 		$219K Buy
+1,191
New +$220K 0.04% 300

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Integrated Wealth Concepts's VRTX Position: Q1 2026 in Review

Integrated Wealth Concepts reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q1 2026, selling an estimated $24.7K and leaving 4,668 shares worth $2.08M. The position accounts for 0.02% of the portfolio, ranked #730.

Integrated Wealth Concepts first reported a position in VRTX in Q1 2019 and has held it in 28 quarters since. The position peaked at $2.38M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Integrated Wealth Concepts held 4,668 shares of Vertex Pharmaceuticals worth $2.08M as of Q1 2026.
  • Integrated Wealth Concepts sold 53 Vertex Pharmaceuticals shares in Q1 2026, an estimated $24.7K.
  • Vertex Pharmaceuticals made up 0.02% of Integrated Wealth Concepts's portfolio in Q1 2026, its #730 holding.
  • Integrated Wealth Concepts first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 28 quarters since.
  • Integrated Wealth Concepts's Vertex Pharmaceuticals position peaked at $2.38M in Q3 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Integrated Wealth Concepts's 13F filing for Q1 2026, filed 15 May 2026.